X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs NOVARTIS - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD NOVARTIS LUPIN LTD/
NOVARTIS
 
P/E (TTM) x 27.4 319.1 8.6% View Chart
P/BV x 2.9 35.4 8.1% View Chart
Dividend Yield % 0.6 1.3 44.8%  

Financials

 LUPIN LTD   NOVARTIS
EQUITY SHARE DATA
    LUPIN LTD
Mar-18
NOVARTIS
Mar-18
LUPIN LTD/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs1,465758 193.3%   
Low Rs727579 125.6%   
Sales per share (Unadj.) Rs349.6228.4 153.1%  
Earnings per share (Unadj.) Rs5.631.7 17.5%  
Cash flow per share (Unadj.) Rs29.632.8 90.3%  
Dividends per share (Unadj.) Rs5.0010.00 50.0%  
Dividend yield (eoy) %0.51.5 30.5%  
Book value per share (Unadj.) Rs300.3297.1 101.1%  
Shares outstanding (eoy) m452.0824.69 1,831.0%   
Bonus/Rights/Conversions ESOPS--  
Price / Sales ratio x3.12.9 107.1%   
Avg P/E ratio x197.221.1 936.3%  
P/CF ratio (eoy) x37.120.4 181.6%  
Price / Book Value ratio x3.62.2 162.2%  
Dividend payout %90.031.5 285.5%   
Avg Mkt Cap Rs m495,50216,505 3,002.1%   
No. of employees `00017.00.7 2,551.2%   
Total wages/salary Rs m28,6471,445 1,982.1%   
Avg. sales/employee Rs Th9,273.68,441.3 109.9%   
Avg. wages/employee Rs Th1,681.02,163.6 77.7%   
Avg. net profit/employee Rs Th147.41,173.1 12.6%   
INCOME DATA
Net Sales Rs m158,0425,639 2,802.8%  
Other income Rs m1,5041,718 87.5%   
Total revenues Rs m159,5457,357 2,168.6%   
Gross profit Rs m31,475-63 -50,360.2%  
Depreciation Rs m10,85925 42,919.8%   
Interest Rs m2,04455 3,695.3%   
Profit before tax Rs m20,0761,575 1,274.5%   
Minority Interest Rs m-710-   
Prior Period Items Rs m350-   
Extraordinary Inc (Exp) Rs m-14,6440-   
Tax Rs m2,885792 364.4%   
Profit after tax Rs m2,513784 320.6%  
Gross profit margin %19.9-1.1 -1,796.8%  
Effective tax rate %14.450.3 28.6%   
Net profit margin %1.613.9 11.4%  
BALANCE SHEET DATA
Current assets Rs m122,0959,522 1,282.3%   
Current liabilities Rs m50,9563,296 1,546.0%   
Net working cap to sales %45.0110.4 40.8%  
Current ratio x2.42.9 82.9%  
Inventory Days Days8537 231.0%  
Debtors Days Days12028 421.9%  
Net fixed assets Rs m129,87646 282,339.8%   
Share capital Rs m904123 732.7%   
"Free" reserves Rs m134,8667,213 1,869.8%   
Net worth Rs m135,7717,336 1,850.6%   
Long term debt Rs m64,2450-   
Total assets Rs m263,05411,105 2,368.7%  
Interest coverage x10.829.5 36.7%   
Debt to equity ratio x0.50-  
Sales to assets ratio x0.60.5 118.3%   
Return on assets %1.77.6 22.9%  
Return on equity %1.910.7 17.3%  
Return on capital %3.722.2 16.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m53,14161 87,691.9%   
Fx outflow Rs m19,3353,630 532.6%   
Net fx Rs m33,807-3,570 -947.1%   
CASH FLOW
From Operations Rs m17,5121,610 1,087.8%  
From Investments Rs m-14,073687 -2,048.4%  
From Financial Activity Rs m-14,921-2,677 557.5%  
Net Cashflow Rs m-11,482-380 3,024.7%  

Share Holding

Indian Promoters % 46.6 0.0 -  
Foreign collaborators % 0.2 75.0 0.3%  
Indian inst/Mut Fund % 11.3 2.0 565.0%  
FIIs % 31.9 1.6 1,993.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 21.5 47.0%  
Shareholders   98,259 41,647 235.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   IPCA LABS  GSK PHARMA  PANACEA BIOTECH  MERCK LTD  SANOFI INDIA  

Compare LUPIN LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Lower; Realty & Auto Stocks Top Losers(09:30 am)

Asian shares eased in holiday-thinned trading on Monday and the safe haven yen gained as China canceled upcoming tariff talks with the United States.

Related Views on News

LUPIN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of LUPIN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of LUPIN LTD. Also includes updates on the valuation of LUPIN LTD.

LUPIN LTD Announces Quarterly Results (1QFY19); Net Profit Up 21.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, LUPIN LTD has posted a net profit of Rs 4 bn (up 21.3% YoY). Sales on the other hand came in at Rs 26 bn (up 3.2% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Sep 24, 2018 01:33 PM

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

LUPIN LTD - GLENMARK PHARMA COMPARISON

COMPARE LUPIN LTD WITH

MARKET STATS